Evy Lundgren-Akerlund, Ph.D., CEO

April 13 | 11:30am | BioCentriq Ballroom 

Lund, Sweden


Xintela is a clinical-stage biopharma company developing allogeneic MSC-based therapies. Xintela’s proprietary product platform XSTEM® consists of homogenous integrin α10β1-selected adipose tissue derived MSCs with superior potency and consistency compared to other MSC technologies. Xintela’s first therapeutic focus is osteoarthritis (OA) and difficult-to-heal venous leg ulcers (VLU). Preclinical studies in large animals, support disease modifying effects in OA and VLU and for treatment of Acute Respiratory Distress Syndrome (ARDS). XSTEM is manufactured in Xintela’s own GMP facility. A First-in-Human study (Phase I/IIa, dose escalation) with XSTEM is ongoing in knee OA patients (KL grade II-III). XSTEM has also entered into Phase I/IIa clinical study for the treatment of difficult-to-heal VLU. During 2023, we expect safety and efficacy readouts from the VLU study as well as safety from all dose levels and early efficacy signals from the OA study.

By using this website you agree to accept our Privacy Policy and Terms & Conditions